Cargando…

Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC

Alectinib is the first-line targeted treatment for advanced ALK-positive non-small-cell lung cancer. Although it has a relatively mild toxicity profile, adverse events (AEs) do occur. We present a case of alectinib-induced bilateral pleural effusions and pericardial effusion that has not previously...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ulhoi, Maiken Parm, Sorensen, Boe Sandahl, Meldgaard, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525301/ https://www.ncbi.nlm.nih.gov/pubmed/34720935 http://dx.doi.org/10.1159/000518081

Ejemplares similares

Tumoral PD-L1 does not impact time to treatment discontinuation in EGFR mutated non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor—a Danish cohort study
por: Dissing, Julie Gabe, et al.
Publicado: (2022)

DNAfusion: an R/Bioconductor package for increased sensitivity of detecting gene fusions in liquid biopsies
por: Maansson, Christoffer Trier, et al.
Publicado: (2023)

Successful Treatment with Ensartinib After Alectinib-induced Hyperbilirubinemia in ALK-Positive NSCLC
por: Peng, Ling, et al.
Publicado: (2021)

Successful salvage surgery followed by second ALK–TKI after alectinib failure in a patient with ALK-positive NSCLC
por: Hashimoto, Hiroshi, et al.
Publicado: (2022)

Cocaine Induced Pleural and Pericardial Effusion Syndrome
por: Alqalyoobi, Shehabaldin, et al.
Publicado: (2015)

Dasatinib-Induced Pleural and Pericardial Effusions
por: Hailan, Yousef M, et al.
Publicado: (2021)

Genomic Profiling of Circulating Tumor DNA Predicts Outcome and Demonstrates Tumor Evolution in ALK-Positive Non-Small Cell Lung Cancer Patients
por: Madsen, Anne Tranberg, et al.
Publicado: (2020)

Alectinib for treating patients with metastatic ALK-positive NSCLC: systematic review and network metanalysis
por: Samacá-Samacá, Daniel, et al.
Publicado: (2023)

Transformation of ALK-positive NSCLC to SCLC after alectinib resistance and response to combined atezolizumab: a case report
por: Xia, Guohao, et al.
Publicado: (2023)

Recurrent Pleural and Pericardial Effusions Due to Sarcoidosis
por: Navaneethan, Sankar D, et al.
Publicado: (2005)

Eosinophilic Endomyocarditis Combined With Pericardial and Pleural Effusion
por: You, Sung-Hye, et al.
Publicado: (2009)

ALK-Positive Squamous Cell Carcinoma Dramatically Responded to Alectinib
por: Sagawa, Ray, et al.
Publicado: (2018)

Alectinib for Miliary Lung Metastasis in ALK-Positive Lung Adenocarcinoma
por: Satoh, Hironori, et al.
Publicado: (2021)

A case of Meigs’ syndrome with preceding pericardial effusion in advance of pleural effusion
por: Okuda, Kenichi, et al.
Publicado: (2016)

Coxsackie B viral infection presenting with hemorrhagic pericardial effusion and pleural effusion
por: Maram, Krishna Prasad, et al.
Publicado: (2022)

Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases—a multicenter retrospective study
por: Zou, Zihua, et al.
Publicado: (2022)

Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC
por: Tran, Phu N., et al.
Publicado: (2016)

Recurrent Pericardial and Pleural Effusion due to Pericardial Pleomorphic Mesothelioma
por: Segura-Méndez, Bárbara, et al.
Publicado: (2022)

Acquired Exon 14 MET Mutation Associated With Resistance to Alectinib in a Patient With ALK–Rearranged NSCLC
por: Daniel, Catherine, et al.
Publicado: (2020)

Two Uncomplicated Pregnancies on Alectinib in a Woman With Metastatic ALK-Rearranged NSCLC: A Case Report
por: Weidenbaum, Chloe, et al.
Publicado: (2022)

STRN-ALK Fusion–Positive Case of Breast Cancer With Response to Alectinib
por: Kelly, Andrew D., et al.
Publicado: (2021)

The potential role of HGF-MET signaling and autophagy in the war of Alectinib versus Crizotinib against ALK-positive NSCLC
por: Huang, Xing
Publicado: (2018)

Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives
por: Karachaliou, Niki, et al.
Publicado: (2019)

THE CYTOLOGY OF EFFUSIONS IN THE PLEURAL, PERICARDIAL AND PERITONEAL CAVITIES
Publicado: (1957)

The efficacy and safety of alectinib in the treatment of ALK+ NSCLC: a systematic review and meta-analysis
por: Fan, Junsheng, et al.
Publicado: (2018)

ALK-positive anaplastic large cell lymphoma that presented as pleural effusion
por: Kim, Do Hwan, et al.
Publicado: (2022)

The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment
por: Demuth, Christina, et al.
Publicado: (2018)

cGAS-STING pathway expression as a prognostic tool in NSCLC
por: Raaby Gammelgaard, Kristine, et al.
Publicado: (2021)

Spontaneous Hemorrhagic Pericardial and Pleural Effusion in a Patient Receiving Apixaban
por: Cinelli, Michael, et al.
Publicado: (2019)

Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC
por: Gadgeel, Shirish, et al.
Publicado: (2018)

Progressive renal insufficiency related to ALK inhibitor, alectinib
por: Nagai, Kojiro, et al.
Publicado: (2018)

Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib
por: Isla, Dolores, et al.
Publicado: (2020)

Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib
por: Takeyasu, Yuki, et al.
Publicado: (2022)

Antibody-guided irradiation of malignant pleural and pericardial effusions.
por: Pectasides, D., et al.
Publicado: (1986)

Pleural, peritoneal and pericardial effusions – a biochemical approach
por: Kopcinovic, Lara Milevoj, et al.
Publicado: (2014)

A Case of Seronegative ANA Hydralazine-Induced Lupus Presenting With Pericardial Effusion and Pleural Effusion
por: Elkholy, Karim O, et al.
Publicado: (2020)

A case report of capillary leak syndrome with recurrent pericardial and pleural effusions
por: Khan, Habib R, et al.
Publicado: (2020)

Pericardial and pleural effusion in an elderly woman with Covid-19 pneumonia: CT findings
por: Messina, Francesco, et al.
Publicado: (2021)

A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan
por: Goto, Yasushi, et al.
Publicado: (2023)

Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
por: Imanishi, Naoko, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_47plqnmunoql3v3lla7s98c6kf